IBB Stock Recent News

What has been the top-performing stock so far of 2024? If you had said server installer Super Micro Computer (NASDAQ: SMCI ), that would be a great answer.

These top-ranked ETFs underperformed the S&P 500 in Q1 of 2024. However, these ETFs have strong potential to rebound in the coming days.

Launched on 02/05/2001, the iShares Biotechnology ETF (IBB) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.

IBB tracks the performance of the rapidly advancing biotechnological sector. The need for advanced medical innovations is urgent to challenge serious ailments. The fund could benefit investors with up to 12% upside potential.

The iShares Biotechnology ETF has underperformed the broader market and remains in the range set last year. Heavily weighted top 10 stocks have flat revenues are are no longer growth stocks. Further upside seems limited, and a long sideways consolidation could develop.

One way to find potentially winning stocks to buy in March, April, and throughout the year is to search for companies gaining more attention from Wall Street analysts.

Growth-focused investors may wish to set their sights on the hard-hit biotech stocks scene as rates begin to retreat, negative momentum settles and the industry catches a bit of a break for once. Of course, to get a higher chance at outsized gains, one must also have a high risk tolerance and a long-enough investment horizon.

Jared Ablass, Vice President, Portfolio Research at TD Asset Management, speaks with Greg Bonnell about how the biotech sector could benefit once rates start to come down. Why beaten down Biotech stocks could be ready for a healthy recovery.

The 'Halftime Report' Investment Committee debates the upside potential in the biotech space.

Mara Goldstein, Biotech Analyst at Mizuho, discusses health care's outperformance this week.